Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a leader in musculoskeletal healthcare, has entered into two new credit agreements totaling $2.5 billion, according to a recent SEC filing. The agreements, consisting of a five-year revolving credit facility and a 364-day revolving credit facility, were both executed on Thursday.
The five-year facility provides the company with $1.5 billion in unsecured credit, maturing on June 28, 2029. Zimmer Biomet has the option to extend the maturity by two additional one-year periods, subject to lender consent. Additionally, the agreement includes a provision that allows the company to request an increase of up to $500 million. Interest rates on borrowings are tied to the company’s credit rating and will fluctuate based on either an adjusted Term SOFR or an alternate base rate.
The 364-day facility offers an additional $1 billion in unsecured credit, set to mature on June 27, 2025. Similar to the five-year agreement, interest rates are dependent on Zimmer Biomet’s credit rating and will be calculated using an adjusted Term SOFR or an alternate base rate.
Both credit agreements contain standard covenants and default provisions for unsecured loans, including restrictions on mergers, asset sales, and maintaining a certain ratio of indebtedness to EBITDA. Specifically, Zimmer Biomet must keep its ratio of consolidated indebtedness to consolidated EBITDA below 4.5 to 1.0, with the possibility to increase to 5.0 to 1.0 under certain conditions.
In conjunction with these new agreements, Zimmer Biomet terminated its previous credit agreements dated July 7, 2023. No outstanding borrowings were reported at the time of termination, and existing letters of credit under the former five-year agreement have been transitioned to the new five-year facility.
The company's engagement with JPMorgan Chase (NYSE:JPM) Bank, N.A., as the administrative agent for the credit facilities, continues a relationship wherein the bank has provided various financial services to Zimmer Biomet for which it has received compensation.
This financial move is part of Zimmer Biomet’s broader strategy to maintain a strong liquidity position and support ongoing operations and corporate activities. The information in this article is based on a press release statement.
In other recent news, Zimmer Biomet Holdings, Inc. has entered into significant partnerships and agreements that highlight the company's ongoing commitment to innovation and growth. The company has formed a multi-year co-marketing agreement with RevelAi Health to enhance value-based orthopedic care through AI-powered solutions. Zimmer Biomet has also announced an exclusive distribution agreement with THINK Surgical, Inc. for the TMINI Miniature Robotic System, which will add to the company's ROSA® Robotics suite, with availability expected in select U.S. markets in the second half of 2024.
In addition to these partnerships, Zimmer Biomet has also entered into a strategic partnership with CBRE Group (NYSE:CBRE), Inc. to develop orthopedic ambulatory surgery centers across the U.S. This move aligns with Zimmer Biomet's strategy to diversify into higher-growth markets. The company's board has also authorized a stock repurchase program of up to $2 billion, showing confidence in the firm's financial health.
In terms of analyst ratings, Piper Sandler and RBC Capital maintained an Overweight and Outperform rating respectively, while Citi and Goldman Sachs reiterated a Neutral stance. These ratings followed Zimmer Biomet's investor day, where the company presented a long-range plan for 2024 to 2027, which includes mid-single-digit revenue growth, increased bottom-line growth, and strategic mergers and acquisitions. These recent developments emphasize Zimmer Biomet's strategic focus on growth and innovation.
InvestingPro Insights
Zimmer Biomet Holdings (NYSE:ZBH) appears to be taking strategic financial steps to strengthen its market position and ensure financial flexibility. According to InvestingPro data, Zimmer Biomet has a market capitalization of $21.8 billion and is trading at a P/E ratio of 22.84, with an adjusted P/E ratio over the last twelve months as of Q1 2024 at 18.17. This indicates a valuation that is potentially attractive relative to near-term earnings growth, as the company also shows a PEG Ratio of 0.2 during the same period, suggesting it could be undervalued based on its earnings trajectory.
InvestingPro Tips reveal that management has been actively buying back shares, which could signal confidence in the company's future performance. Additionally, Zimmer Biomet has a history of maintaining dividend payments, with a consistent track record for 13 consecutive years. The dividend yield as of mid-2023 stands at 0.88%, which could be appealing for income-focused investors. For readers looking for more in-depth analysis, there are additional InvestingPro Tips available, including the fact that 21 analysts have revised their earnings expectations downwards for the upcoming period, which should be considered when evaluating the company's prospects.
For those interested in gaining further insights and tips on Zimmer Biomet, consider subscribing to InvestingPro. Use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.